GlassScriptPhysician profile
Angela P Black
NPI 1972671733
$1,082.35
in general payments reported to CMS, 2019-2025
22 companies · $315 in 2025
The $315 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.04 · 2020: $39.43 · 2021: $68.06 · 2022: $73.46 · 2023: $266 · 2024: $239 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $820.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $252.83 | 2023-2025 | Bexsero |
| Cranial Technologies, INC | $122.03 | 2022-2025 | Doc Band |
| Supernus Pharmaceuticals, INC. | $113.37 | 2023-2025 | Qelbree, Qelbree |
| Sanofi Pasteur INC. | $98.89 | 2019-2025 | |
| Corium, LLC | $52.73 | 2023-2024 | Azstarys |
| Collegium Pharmaceutical, INC. | $47.81 | 2025 | Jornay Pm |
| Tris Pharma INC | $45.56 | 2019-2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $42.68 | 2019-2024 | |
| Welch Allyn | $38.97 | 2021 | |
| Baxter Healthcare | $38.97 | 2022 | |
| Acadia Pharmaceuticals INC | $34.44 | 2023 | Daybue |
| Cipher Pharmaceuticals US LLC | $23.72 | 2025 | Natroba, Spinosad |
| Ultragenyx Pharmaceutical INC. | $23.34 | 2023 | |
| Abbott Laboratories | $22.51 | 2020 | |
| Verrica Pharmaceuticals INC. | $17.84 | 2024 | Ycanth |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $17.70 | 2025 | Alvesco |
| Takeda Pharmaceuticals U.S.A., INC. | $17.58 | 2021 | |
| Neos Therapeutics, LP | $16.92 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.38 | 2019 | |
| Pfizer INC. | $14.21 | 2024 | |
| Photonicare INC | $13.87 | 2024 | Otosight Middle Ear Scope |
| Genentech USA, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.